Nasca V, Bergamo F, Foltran L, Antonuzzo L, et al. Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical BMC Cancer 2025;25:633.
PMID: 40200187